PROCEDURES PRO

INTERCOSTAL BLOCKS FOR RIB FRACTURES

Katherine Bennett, DVM Christine Egger, DVM, MVSc, CVA, CVH, DACVAA University of Tennessee



Pain associated with thoracic trauma, whether surgically induced or traumatic in origin, can lead to hypoventilation, delayed recovery, increased morbidity, and prolonged hospitalization.^{1,2} Local anesthesia at the level of the intercostal spaces provides benefits over thoracic epidural anesthesia by inducing less sympathetic blockade, addressing pain closer to the initiation of the pain pathway, and providing complete blockade of all pain fibers, with minimal effect on ventilation.³ Intercostal nerve blocks have been shown to improve pulmonary function in the postoperative period in human and veterinary patients undergoing thoracotomy⁴⁻⁶; in addition, in humans, intercostal nerve blocks used to treat multiple rib fractures have been

shown to be effective and to decrease the amount of systemic opioid needed to control pain. 5 Dogs and cats with multiple rib fractures are at risk for decreased pulmonary function and may require high rates of systemic analgesics to control pain.7

Relevant Anatomy

The paravertebral space involves the spinal nerve root, which is continuous with the intercostal nerve. This space is not completely segregated; drugs injected into one specific paravertebral space have the potential to spread cranially and caudally into additional paravertebral spaces, as well as medially and laterally into the epidural and intercostal spaces. The intercostal space is continuous

TABLE

LOCAL PERINEURAL ANESTHETIC DOSAGES¹⁻³

Drug (Concentration)*	Duration of Action**	Dose (Dogs)	Maximum Dose (Dogs)	Dose (Cats)	Maximum Dose (Cats)
Bupivacaine (0.5% or 0.25%)	4-12 hr (average, ≈6-8 hr)	0.5-1 mg/kg	2 mg/kg	0.25-0.50 mg/kg	1 mg/kg
Lidocaine (2%)	1-2 hr (average, ≈90 min)	1-2 mg/kg	5-6 mg/kg	0.5-1 mg/kg Note: Systemic uptake should be avoided by ensuring the block does not go intravenously	1-2 mg/kg
Morphine (10 mg/ mL or 25 mg/mL)	4-6 hr	0.1 mg/kg		0.1 mg/kg	
Methadone (10 mg/mL)	4-6 hr	0.1 mg/kg		0.1 mg/kg	
Dexmedetomidine (0.5 mg/mL)	4-6 hr	1-2 µg/kg		1-2 µg/kg	

^{*} Onset of local analgesia can take up to 20 minutes but depends on the drug(s) used. Rapid-onset drugs (eg, lidocaine, α_2 agonists) can be added to those with slower onset (eg, bupivacaine, opioids) to facilitate a faster onset of analgesia.

^{**} The duration of the block itself is altered by the agents and dose selected for each patient.

with the paravertebral space and involves the nerve roots that branch from the paravertebral nerve and supply the ribs, intercostal muscles, and skin. In general, the neurovascular structures that line the thoracic cavity have both cranial and caudal branches, which divide and supply the skin and intercostal muscles of segments adjacent to that paravertebral space.

Due to this collateral circulation/innervation, blocking sites adjacent to rib fractures is recommended to ensure appropriate analgesia to the intended site. Risks associated with this procedure include iatrogenic pneumothorax, intraneural or intravascular injection, systemic toxicity of local anesthetics, and, rarely, introduction of bacteria into the intercostal or paravertebral space.

Agents for Intercostal Blocks

Drugs used in intercostal blocks can include local anesthetics, opioids, or α_2 agonists; a combination of drugs is often recommended to increase effects on the pain pathway.^{1,2,5,8} Bupivacaine, a local anesthetic that provides long-term pain relief, is often recommended because it provides 6 to 8 hours of blockade.9 Mixing bupivacaine with either an opioid (eg, preservative-free morphine) or an α_2 agonist (eg, dexmedetomidine) can provide additional analgesia by activating local opioid and α2 receptors and through systemic absorption.¹⁰ A study in humans noted that the risk for local anesthetic toxicity is highest when local anesthetics are administered at the paravertebral space, and another noted that local anesthetics are also rapidly absorbed from the intercostal space.9

Care should be taken when calculating drug dosages (*Table*), and the effects of systemic absorption of local anesthetics and adjunctive agents should be considered. If there are multiple rib fracture sites and more volume is needed to appropriately block all ribs,

decreasing the dose of bupivacaine and adding lidocaine to increase the volume is ideal; however, this will decrease the overall duration of action. Adding sterile water (or saline) to the volume of local anesthetic may also be appropriate. After the number of fractured ribs is determined, the number of sites to block and the number of aliquots of local anesthetic to prepare should be calculated (see *Calculating Intercostal Sites*). If multiple ribs are broken on one side, many of these sites will overlap cranially and caudally.

CALCULATING INTERCOSTAL SITES

Fracture Site (rib #) = 7 Cranial Intercostal Spaces: 5-6, 6-7 Affected Space: 7-8 Caudal Intercostal Spaces: 8-9, 9-10 Total Spaces to Block: 5

Fracture Site (rib #) = 4, 6 Cranial Intercostal Spaces: 2-3, 3-4; 4-5, 5-6 Affected Spaces: 4-5, 6-7 Caudal Intercostal Spaces: 5-6, 6-7; 7-8, 8-9 Total Spaces to Block: 8 (Note: Several of these spaces overlap between the 2 fracture sites.)

Blocking sites adjacent to rib fractures is recommended to ensure appropriate analgesia to the intended site.

WHAT YOU WILL NEED

- ► Clippers and preparation supplies (eg, chlorhexidine scrub, alcohol)
- ▶ Gloves
- ► Selected drugs divided into aliquots based on number of sites to block (see Calculating Intercostal Sites, previous page)
- ► Aliquots of sterile saline
- ► New spinal or hypodermic needle (22-25 g) for each site

STEP-BY-STEP INTERCOSTAL BLOCKS FOR RIB FRACTURES

STEP 1

Sedate (or anesthetize, if needed) the patient using an opioid and either a benzodiazepine or an α_2 agonist, depending on the patient's overall cardiovascular and systemic health status.¹¹

Author Insight

If the patient has suffered fractures due to trauma, electrocardiography and close monitoring should be instituted to observe for evidence of cardiac contusions in the form of arrhythmias. The presence of arrhythmias may change the drug choice for sedation, general anesthesia, and/or paravertebral local blocks.

STEP 2

Obtain thoracic radiographs to confirm the location of the broken rib(s).

STEP 3

Block at least 2 intercostal spaces cranial to and caudal to the fracture on the ipsilateral side to deliver complete analgesia to the fracture site (see Calculating Intercostal Sites, previous page). Count sites multiple times to ensure the appropriate spaces are blocked. While wearing gloves, clip long hair at the injection site if needed for accurate palpation, and clear the site of debris and obvious contamination.



STEP 4

Place the patient in lateral recumbency with the injured side up, and ensure supplemental oxygen is being provided. Insert a small (<22-gauge) spinal needle as dorsally as possible (near the intervertebral foramen) at the very caudal border of the rib cranial to the desired intercostal space.



Mask oxygen is considered adequate if the patient is not receiving additional support (eg, nasal cannulas). If the patient already has a nasal cannula, this is preferred over a mask but does not need to be placed solely for this procedure.





STEP 5

Walk off the rib surface in a caudal direction, then aspirate with a syringe containing a small amount of sterile saline to confirm that the needle is not in a vessel or in the thoracic cavity.

Author Insight

Imaging (eg, ultrasonography, fluoroscopy) can help indicate the correct location.



STEP 6

Inject a small amount of sterile saline. If there is no resistance, disconnect this syringe and connect the syringe of local anesthetic; if resistance is encountered, carefully redirect the needle, using caution not to enter the thoracic cavity. Slowly inject the total volume for the site over 2 minutes. Repeat the process for each additional site. Monitor the patient for changes in respiratory rate/character or signs of respiratory distress that may be indicative of a pneumothorax.

STEP 7

Continue with supplemental oxygen, and perform thoracocentesis if pneumothorax is suspected.

References

- 1. Pavlidou K, Papazoglou L, Savvas I, Kazakos G. Analgesia for small animal thoracic surgery. Compend Contin Educ Vet. 2009;31(9):432-436.
- 2. Thompson SE, Johnson JM. Analgesia in dogs after intercostal thoracotomy. A comparison of morphine, selective intercostal nerve block, and interpleural regional analgesia with bupivacaine. Vet Surg. 1991;20(1):73-77.
- 3. Garcia ER. Local anesthetics. In: Grimm KA, Lamont LA, Tranquilli WJ, Greene SA, Robertson SA, eds. Veterinary Anesthesia and Analaesia: The Fifth Edition of Lumb and Jones. Ames. IA: John Wiley & Sons: 2015:332-355.
- 4. Hutchins J, Apostolidou I, Shumway S, et al. Paravertebral catheter use for postoperative pain control in patients after lung transplant surgery: a prospective observational study. J Cardiothorac Vasc Anesth. 2017;31(1):142-146.
- 5. Michelet P, Boussen S. Case scenario thoracic trauma. Ann Fr Anesth Reanim. 2013;32(7-8): 504-509.
- 6. Špiček-Macan J, Stančić-Rokotov D, Hodoba N, Kolarić N, Cesarec V, Pavlović L. Thoracic paravertebral nerve block as the sole anesthetic for an open biopsy of a large anterior mediastinal mass. J Cardiothorac Vasc Anesth. 2014;28(4):1032-1039.
- 7. Shih A, Martins A. Disorders related to trauma. In: Snyder LBC, Johnson RA, eds. Canine & Feline Anesthesia & Co-Existing Disease. Ames, IA: John Wiley & Sons; 2015:320-330.
- 8. Karmakar MK, Critchley LA, Ho AM, Gin T, Lee TW, Yim AP. Continuous thoracic paravertebral infusion of bupivacaine for pain management in patients with multiple fractured ribs. Chest. 2003;123(2):424-431.
- 9. Kopacz DJ, Emanuelsson BM, Thompson GE, Carpenter RL, Stephenson CA. Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. Anesthesiology. 1994;81(5):1139-1148.
- 10. Egger CM, Love L. Local and regional anesthesia techniques, part 2: stifle, intercostal, intrapleural, and forelimb techniques. Vet Med. 2009;104:130-138.
- Hidalgo NRA, Ferrante FM. Complications of paravertebral, intercostal nerve blocks and interpleural analgesia. In: Finucane BT, ed. Complications of Regional Anesthesia. 2nd ed. Edmondton, Alberta: Springer Science+Business Media; 2007:102-121.



30 mg/mL

BRIEF SUMMARY: Before using this product, please consult the full product insert for more information.

For oral use in dogs only

Appetite Stimulant

Caution: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

Description: ENTYCE® (capromorelin oral solution) is a selective ghrelin receptor agonist that binds to receptors and affects signaling in the hypothalamus to cause appetite stimulation and binds to the growth hormone secretagogue receptor in the pituitary gland to increase growth hormone secretion

Indication: ENTYCE (capromorelin oral solution) is indicated for appetite stimulation in dogs

Contraindications: ENTYCE should not be used in dogs that have a hypersensitivity

Warnings: Not for use in humans. Keep this and all medications out of reach of children and pets. Consult a physician in case of accidental ingestion by humans. For use in dogs only

Precautions: Use with caution in dogs with hepatic dysfunction. ENTYCE is metabolized by CYP3A4 and CYP3A5 enzymes (See Clinical Pharmacology). Use with caution in dogs with renal insufficiency. ENTYCE is excreted approximately 37% in urine and 62% in feces (See Adverse Reactions and Clinical Pharmacology).

The safe use of ENTYCE has not been evaluated in dogs used for breeding or pregnant or lactating bitches.

Adverse Reactions: Field safety was evaluated in 244 dogs. The most common adverse reactions were diarrhea and vomiting. Of the dogs that received ENTYCE (n = 171), 12 experienced diarrhea and 11 experienced vomiting. Of the dogs treated with placebo (n = 73), 5 experienced diarrhea and 4 experienced vomiting

To report suspected adverse drug events and/or obtain a copy of the Safety Data Sheet (SDS) or for technical assistance, call Aratana Therapeutics at 1-844-640-5500.

For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS or online at http://www.fda.gov/Animal Veterinary/SafetyHealth

NADA 141-457, Approved by FDA

US Patent: 6,673,929 US Patent: 9,700,591 Made in Canada



Aratana Therapeutics, Inc. Leawood, KS 66211

ENTYCE is a trademark of Aratana Therapeutics, Inc. © Aratana Therapeutics, Inc.

AT2-051-1

February 2018